ENJAYMO Patient Solutions

ENJAYMO Patient
Solutions

Access Support

When starting treatment with ENJAYMO, you may be looking for information about your condition, treatment, insurance assistance, and more. Here are some of the areas of support available to you through ENJAYMO Patient Solutions:

  • Disease and treatment education
  • Help in understanding insurance coverage and options
  • Financial assistance programs to help eligible patients with treatment or infusion-related costs
  • Infusion process information and education
  • Assistance identifying other resources and support available to you
ENJAYMO

Patient Solutions
is Here to Help

ENJAYMO Patient Solutions is here to help support you through your treatment journey. We're available to assist you Monday through Friday, 8 AM to 8 PM ET, at 1-833-223-2428.

Meet the Team That's Ready to Support You

When you enroll in ENJAYMO Patient Solutions, you gain access to a dedicated team that can connect you with education and a range of resources on ENJAYMO.
Case Manager Icon

Case Managers

Case managers are experienced in helping individuals get started on treatment and assisting with insurance-related needs. They are also an ongoing resource should you need additional support along the way.
Therapeutic Education Managers Icon

Therapeutic Education
Managers (TEMs)

Therapeutic Education Managers, or TEMs, are available to provide education about ENJAYMO and CAD. TEMs help raise awareness about CAD in the community and educate patients and caregivers. They engage with patients to provide information and facilitate educational events about ENJAYMO and CAD. Talk to your Case Manager to learn more about how to contact a TEM.
TEMs are paid to provide educational services on behalf of Sanofi Genzyme. They do not provide medical advice. You should always talk to your doctor about any healthcare needs.

Financial Assistance Programs

ENJAYMO Patient Solutions financial assistance programs provide support for eligible patients who wouldn't be able to access ENJAYMO otherwise.
Co-Pay Assistance Program Icon

Co-Pay Assistance
Program

ENJAYMO Co-Pay Assistance Program may be able to help with eligible patients' treatment costs, such as out-of-pocket, co-payments or co-insurance, and cost of infusion if they meet the program requirements.*
Patient Assistance Program Icon

Patient Assistance
Program

ENJAYMO Patient Assistance Program provides financial support for eligible patients who have limited access to treatment due to insurance issues and financial challenges.
*The ENJAYMO Patient Solutions Co-Pay program (the "Program") is not valid for prescriptions covered by or submitted for reimbursement under Medicare, Medicaid, VA, DoD, TRICARE® or similar federal or state programs, including any state pharmaceutical assistance programs. The Program is not valid where prohibited by law, and savings may vary depending on patients' out-of-pocket costs. Sanofi Genzyme reserves the right to modify or terminate the Program at any time without notice. Patients will receive all Program details upon registration.
ENJAYMO Patient Solutions Enrollment Form Icon

ENJAYMO
Enrollment Form

If you've been prescribed ENJAYMO, work with your doctor to complete the ENJAYMO Patient Solutions Enrollment Form to get started with support services that are available to you.

Stay Connected Icon Sign Up to
Stay Informed

Whether you're taking ENJAYMO or interested in learning more, sign up to receive additional information, resources, and helpful tools to support you on your journey with Cold Agglutinin Disease.

Sign Up Now
×
INDICATION

ENJAYMO is a prescription medicine used to treat the breakdown of red blood cells (hemolysis) in adults with Cold Agglutinin Disease (CAD). It is not known if ENJAYMO is safe and effective in children.

IMPORTANT SAFETY INFORMATION AND INDICATION
+
INDICATION

ENJAYMO is a prescription medicine used to decrease the need for red blood cell transfusion due to the breakdown of red blood cells (hemolysis) in adults with cold agglutinin disease (CAD).

It is not known if ENJAYMO is safe and effective in children.

IMPORTANT SAFETY INFORMATION

Do not receive ENJAYMO if you are allergic to sutimlimab-jome or any of the ingredients in ENJAYMO.

ENJAYMO can cause serious side effects, including:

  • Serious Infections: ENJAYMO is a prescription medicine that affects a part of your immune system. ENJAYMO can lower the ability of your immune system to fight infections. People who take ENJAYMO may have an increased risk of getting infections caused by certain kinds of bacteria such as Neisseria meningitides, Streptococcus pneumoniae, and Haemophilus influenzae. These infections may be serious or life-threatening. Some infections may quickly become life-threatening or cause death if not recognized and treated early.
    • You need to receive vaccinations against infections caused by certain kinds of bacteria at least 2 weeks before your first dose of ENJAYMO. You may need to have additional vaccinations during treatment
    • If your healthcare provider decides that urgent treatment with ENJAYMO is needed, you should receive vaccinations as soon as possible.
    • Vaccinations may reduce the risk of these infections, but do not prevent all infections. Call your healthcare provider or get medical help right away if you get any new signs and symptoms of an infection, including:

      • fever
      • severe headache with stiff neck or back
      • pain during urination or urinating more often than usual
      • cough or difficulty breathing
      • flu-like symptoms
      • pain, redness or swelling of the skin
  • Infusion-related reactions: Treatment with ENJAYMO may cause infusion-related reactions, including allergic reactions that may be serious or life-threatening. Your healthcare provider may slow down or stop your ENJAYMO infusion if you have an infusion-related reaction, and will treat your symptoms if needed. Tell your healthcare provider right away if you develop symptoms during your ENJAYMO infusion that may mean you are having an infusion-related reaction, including
    • shortness of breath
    • rapid heartbeat
    • nausea
    • flushing
    • headache
  • Risk of autoimmune disease: ENJAYMO may increase your risk for developing an autoimmune disease such as systemic lupus erythematosus (SLE). Tell your healthcare provider and get medical help if you develop any symptoms of SLE, including:
    • joint pain or swelling
    • rash on the cheeks and nose
    • unexplained fever
  • If you have CAD and you stop receiving ENJAYMO, your healthcare provider should monitor you closely for return of your symptoms after you stop ENJAYMO. Stopping ENJAYMO may cause the breakdown of your red blood cells due to CAD to return. Symptoms or problems that can happen due to red blood cell breakdown include:
    • tiredness
    • shortness of breath
    • rapid heart rate
    • blood in your urine or dark urine

The most common side effects of ENJAYMO include:

  • respiratory tract infection
  • viral infection
  • diarrhea
  • indigestion
  • cough
  • joint pain
  • joint inflammation (arthritis)
  • Arthralgia
  • swelling of the lower legs, ankles, and feet

These are not all the possible side effects of ENJAYMO. Call your doctor for medical advice about side effects.

Before receiving ENJAYMO, tell your healthcare provider about all of your medical conditions, including if you:

  • have a fever or infection, including a history of human immunodeficiency virus (HIV), hepatitis B, or hepatitis C.
  • have an autoimmune disease such as systemic lupus erythematosus (SLE), also known as lupus.
  • are pregnant or plan to become pregnant. It is not known if ENJAYMO will harm your unborn baby.
  • are breastfeeding or plan to breastfeed. It is not known if ENJAYMO passes into your breast milk.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

Please see Full Prescribing Information, including Medication Guide.

×
INDICATION

ENJAYMO is a prescription medicine used to decrease the need for red blood cell transfusion due to the breakdown of red blood cells (hemolysis) in adults with cold agglutinin disease (CAD).

It is not known if ENJAYMO is safe and effective in children.

IMPORTANT SAFETY INFORMATION AND INDICATION
+
INDICATION

ENJAYMO is a prescription medicine used to decrease the need for red blood cell transfusion due to the breakdown of red blood cells (hemolysis) in adults with cold agglutinin disease (CAD).

It is not known if ENJAYMO is safe and effective in children.

IMPORTANT SAFETY INFORMATION

Do not receive ENJAYMO if you are allergic to sutimlimab-jome or any of the ingredients in ENJAYMO.

ENJAYMO can cause serious side effects, including:

  • Serious Infections: ENJAYMO is a prescription medicine that affects a part of your immune system. ENJAYMO can lower the ability of your immune system to fight infections. People who take ENJAYMO may have an increased risk of getting infections caused by certain kinds of bacteria such as Neisseria meningitides, Streptococcus pneumoniae, and Haemophilus influenzae. These infections may be serious or life-threatening. Some infections may quickly become life-threatening or cause death if not recognized and treated early.
    • You need to receive vaccinations against infections caused by certain kinds of bacteria at least 2 weeks before your first dose of ENJAYMO. You may need to have additional vaccinations during treatment
    • If your healthcare provider decides that urgent treatment with ENJAYMO is needed, you should receive vaccinations as soon as possible.
    • Vaccinations may reduce the risk of these infections, but do not prevent all infections. Call your healthcare provider or get medical help right away if you get any new signs and symptoms of an infection, including:

      • fever
      • severe headache with stiff
        neck or back
      • pain during urination or urinating
        more often than usual
      • cough or difficulty breathing
      • flu-like symptoms
      • pain, redness or
        swelling of the skin
  • Infusion-related reactions: Treatment with ENJAYMO may cause infusion-related reactions, including allergic reactions that may be serious or life-threatening. Your healthcare provider may slow down or stop your ENJAYMO infusion if you have an infusion-related reaction, and will treat your symptoms if needed. Tell your healthcare provider right away if you develop symptoms during your ENJAYMO infusion that may mean you are having an infusion-related reaction, including:
    • shortness of breath
    • rapid heartbeat
    • nausea
    • flushing
    • headache
  • Risk of autoimmune disease: ENJAYMO may increase your risk for developing an autoimmune disease such as systemic lupus erythematosus (SLE). Tell your healthcare provider and get medical help if you develop any symptoms of SLE, including:
    • joint pain or swelling
    • rash on the cheeks and nose
    • unexplained fever
  • If you have CAD and you stop receiving ENJAYMO, your healthcare provider should monitor you closely for return of your symptoms after you stop ENJAYMO. Stopping ENJAYMO may cause the breakdown of your red blood cells due to CAD to return. Symptoms or problems that can happen due to red blood cell breakdown include:
    • tiredness
    • shortness of breath
    • rapid heart rate
    • blood in your urine or dark urine

The most common side effects of ENJAYMO include:

  • respiratory tract infection
  • viral infection
  • diarrhea
  • indigestion
  • cough
  • joint pain
  • joint inflammation (arthritis)
  • swelling of the lower legs, ankles, and feet

These are not all the possible side effects of ENJAYMO. Call your doctor for medical advice about side effects.

Before receiving ENJAYMO, tell your healthcare provider about all of your medical conditions, including if you:

  • have a fever or infection, including a history of human immunodeficiency virus (HIV), hepatitis B, or hepatitis C.
  • have an autoimmune disease such as systemic lupus erythematosus (SLE), also known as lupus.
  • are pregnant or plan to become pregnant. It is not known if ENJAYMO will harm your unborn baby.
  • are breastfeeding or plan to breastfeed. It is not known if ENJAYMO passes into your breast milk.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

Please see Full Prescribing Information, including Medication Guide.